It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
CRISPR/Cas9 represents a valuable tool to determine protein function, but technical hurdles limit its use in challenging settings such as cells unable to grow in vitro like primary leukemia cells and xenografts derived thereof (PDX). To enrich CRISPR/Cas9-edited cells, we improved a dual-reporter system and cloned the genomic target sequences of the gene of interest (GOI) upstream of an out-of-frame fluorochrome which was expressed only upon successful gene editing. To reduce rounds of in vivo passaging required for PDX leukemia growth, targets of 17 GOI were cloned in a row, flanked by an improved linker, and PDX cells were lentivirally transduced for stable expression. The reporter enriched scarce, successfully gene-edited PDX cells as high as 80%. Using the reporter, we show that KO of the SRC-family kinase LYN increased the response of PDX cells of B precursor cell ALL towards Vincristine, even upon heterozygous KO, indicating haploinsufficiency. In summary, our reporter system enables enriching KO cells in technically challenging settings and extends the use of gene editing to highly patient-related model systems.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Helmholtz Zentrum München, Research Unit Apoptosis in Hematopoietic Stem Cells, German Research Center for Environmental Health (HMGU), Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
2 Helmholtz Zentrum München, Research Unit Apoptosis in Hematopoietic Stem Cells, German Research Center for Environmental Health (HMGU), Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany (GRID:grid.4567.0); Ludwig Maximilian University, Department of Pediatrics, Dr. von Hauner Children’s Hospital, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)